FindTrial
Sign In

AC220

DRUG7 trials

Sponsors

Daiichi Sankyo, Cardiff University, Therapeutic Advances in Childhood Leukemia Consortium, Daiichi Sankyo Co., Ltd.

Conditions

AMLAcute Myeloid LeukaemiaAcute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeLeukemiaLeukemia, Myeloid, AcuteLymphoblastic Leukemia, Acute, ChildhoodMDS

Phase 1

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
CompletedNCT00462761
Daiichi SankyoAcute Myeloid Leukemia, AML, Leukemia +2
Start: 2007-01-31End: 2009-12-31Updated: 2020-05-11
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
CompletedNCT01236144
Cardiff UniversityAcute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome
Start: 2011-04-30End: 2014-01-31Updated: 2014-06-11
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
CompletedNCT01390337
Daiichi SankyoLeukemia, Myeloid, Acute
Start: 2011-10-31End: 2015-02-28Updated: 2019-02-12
AC220 for Children With Relapsed/Refractory ALL or AML
CompletedNCT01411267
Therapeutic Advances in Childhood Leukemia ConsortiumLymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
Start: 2011-09-01End: 2013-09-12Updated: 2022-04-04
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
CompletedNCT01468467
Daiichi SankyoLeukemia, Myeloid, Acute
Start: 2012-04-30End: 2015-03-31Updated: 2019-02-12
Phase 1 Study of Quizartinib
CompletedNCT02675478
Daiichi Sankyo Co., Ltd.Refractory AML, Relapsed AML
Start: 2016-02-29End: 2018-11-13Updated: 2019-02-12

Phase 2

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
CompletedNCT01565668
Daiichi SankyoLeukemia, Myeloid, Acute
Start: 2012-04-30End: 2015-03-31Updated: 2019-12-27

Related Papers

Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.
2019-07-2916 citations
Targeted Chemotherapy vs. Immuno-Based Therapies in AML
Oncology Times2018-11-14
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML
Blood2018-06-06148 citations
Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with <i>FLT3</i>-ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.
Journal of Clinical Oncology2018-05-202 citations
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
American Journal of Hematology2017-11-1592 citations
Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.
Journal of Clinical Oncology2014-05-2027 citations
The benefit of treatment with quizartinib and subsequent bridging to HSCT for FLT3-ITD(+) patients with AML.
Journal of Clinical Oncology2014-05-209 citations